NASDAQ Soins de santé Biotechnologie OCGN

Ocugen, Inc.

$ 1.24 0.81 %

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

CEO: Shankar Musunuri - https://www.ocugen.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$5 303.23 %

Recommandation

Buy

DCF

$ -0.20

Loading data...

OCGN vs S&P500

Loading data...

No data available.

Quick ratio

1.86

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-5.17

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.24

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-127 987.50 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-157.55 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

14.73

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

5.74

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-0.19

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
-8.99 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.54 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.59 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.